Dossier assessment
Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Glycopyrronium bromide (sialorrhoea) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders
Added benefit not proven as the appropriate comparator therapy (best supportive care) was not implemented in any of the studies
Press releases
Haemophilia A and sialorrhoea: comparator therapies not implemented, added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-09-20 A G-BA decision was published.
Project details
- Project no.
- A18-22
- Commission
- Commission awarded on 29.03.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.